About HeartSciences

We're on a mission to transform cardiovascular care through AI-powered early detection, making advanced cardiac diagnostics accessible at the point of care.

Our Mission

Cardiovascular disease remains the leading cause of death globally, often because critical conditions go undetected until it's too late. Traditional ECG interpretation misses subtle signs that could enable earlier intervention.

HeartSciences was founded to change that. By combining advanced AI algorithms with clinical-grade ECG acquisition, we're enabling healthcare providers to detect cardiac abnormalities earlier than ever before.

Our technology is the result of years of research, rigorous clinical validation, and collaboration with leading healthcare institutions around the world.

Mission Image

Our Values

Patient First

Everything we do is guided by our commitment to improving patient outcomes.

Scientific Rigor

Our technology is built on a foundation of peer-reviewed clinical research.

Integrity

We maintain the highest standards of ethics in everything we do.

Innovation

We continuously push the boundaries of what AI can achieve in healthcare.

Leadership Team

Our team brings together expertise in AI, cardiology, medical devices, and healthcare innovation.

DMA

Dr. Mark Anderson

Chief Executive Officer

Former cardiology professor with 20+ years in medical device innovation.

DSC

Dr. Sarah Chen

Chief Medical Officer

Board-certified cardiologist and AI researcher from Stanford.

MR

Michael Rodriguez

Chief Technology Officer

Former Google Health engineer specializing in medical AI systems.

JW

Jennifer Williams

Chief Commercial Officer

15 years scaling healthcare technology companies globally.

Company Milestones

2015

Company Founded

HeartSciences established with a mission to transform cardiac diagnostics.

2017

First Algorithm

Development of initial AI algorithm for diastolic dysfunction detection.

2019

Clinical Trials

Multi-center clinical validation studies initiated across 12 medical centers.

2021

FDA Clearance

Received 510(k) clearance for MyoVista Insights software.

2022

Commercial Launch

Full commercial availability in the United States.

2023

International Expansion

CE marking obtained, expansion into European markets.

2024

Algorithm Expansion

Enhanced clearance for 12+ cardiac condition detection algorithms.

Schedule Your Demo Today

See how HeartSciences can transform cardiovascular care at your institution. Our team will walk you through the platform and answer all your questions.

Personalized platform demonstration
Clinical evidence review
Custom pricing and implementation plan
No obligation consultation

Request a Demo

By submitting, you agree to our Privacy Policy.